Logos Global Management »

Dianthus Therapeutics shares owned by Logos Global Management

Quarter-by-quarter ownership of Dianthus Therapeutics (DNTH) shares owned by Logos Global Management from 13F filings

Historical chart of Logos Global Management investment in Dianthus Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Dianthus Therapeutics held by Logos Global Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Dianthus Therapeutics by Logos Global Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $7.9M 200k 39.35

More positions owned by Logos Global Management

Revolution Medicines Call Option (RVMD)
Ideaya Biosciences Call Option (IDYA)
Akero Therapeutics (AKRO)
Arvinas Ord (ARVN)
Ocular Therapeutix (OCUL)
Cidara Therapeutics Com New (CDTX)
Verastem Com New (VSTM)
Abivax Sa Sponsored Ads (ABVX)
Janux Therapeutics (JANX)
Erasca (ERAS)
Maze Therapeatics (MAZE)
Olema Pharmaceuticals (OLMA)
Immunocore Hldgs Ads (IMCR)
Dyne Therapeutics (DYN)
Disc Medicine (IRON)

View all positions for Logos Global Management

Top funds holding Dianthus Therapeutics

FMR
Fairmount Funds Management
Avidity Partners Management
RA Capital Management
Wellington Management Company
Octagon Capital Advisors
Point72 Asset Management
TCG Crossover Management
Vanguard Group
BlackRock
Bain Capital Life Sciences Investors
Vestal Point Capital
Citadel Advisors
VR Adviser
Alliancebernstein

View all funds holding Dianthus Therapeutics